Skip to main content
TipRanks
Go Ultimate75% OFF

Firefly Neuroscience (AIFF) AI Stock Analysis

387 Followers
AIFF

Firefly Neuroscience

(NASDAQ:AIFF)

Select Model
Rating:44Neutral
Price Target:$0.88â–¼(-3.18% Downside)
Action:reiterated
Date:11/10/26

The score is weighed down primarily by very large operating losses and persistent negative free cash flow despite improving revenue growth. Technicals also remain bearish with the stock below major moving averages and negative MACD. A stronger balance sheet (no debt, positive equity) helps mitigate risk but is not enough to offset weak profitability and cash burn.

Positive Factors
Revenue GrowthThe increase in trailing-twelve-month revenue shows that Firefly is achieving measurable commercial traction in its neuroscience software market. Continued adoption would improve operating leverage over time, support investment in product development, and create a stronger foundation for eventual profitability.
Negative Factors
Severe Operating LossesExtremely negative operating and net margins show that the current revenue base is far below the cost structure required to run the business. Unless revenue scales substantially or expenses decline, these losses will continue to weaken equity, restrict reinvestment capacity, and delay sustainable profitability.

Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%100%AIFF-39.60%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$13.94M
Dividend Yield
―
Average Volume (3M)
2.66M
Price to Earnings (P/E)
-1.8
Beta (1Y)
1.55
Revenue Growth
162.84%
EPS Growth
80.71%
Country
US
Employees
17
Sector
Technology
Sector Strength
61
Industry
Software - Application

Firefly Neuroscience Business Overview & Revenue Model

Company Description

Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by...

Firefly Neuroscience Financial Statement Overview

Summary

Revenue is growing (TTM ~$2.06M, +14.4%), and the balance sheet is materially cleaner with zero debt and positive equity (~$13.43M). However, results are still dominated by extremely large losses (EBIT margin ~-504%, net margin ~-506%) and heavy cash burn (TTM operating cash flow ~$-6.63M; free cash flow ~$-6.66M), keeping overall financial quality weak.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.06M1.14M108.00K498.00K032.00K
Gross Profit1.18M645.00K41.00K498.00K032.00K
EBITDA-7.90M-19.55M-10.32M-2.58M-3.20M-3.82M
Net Income-7.95M-19.88M-10.46M-2.60M-3.79M-4.38M
Balance Sheet
Total Assets15.45M10.48M4.60M2.64M135.00K953.00K
Cash, Cash Equivalents and Short-Term Investments8.02M2.75M1.81M2.14M58.00K653.00K
Total Debt00694.00K001.79M
Total Liabilities2.02M2.84M4.98M2.53M2.25M3.97M
Stockholders Equity13.43M7.64M-375.00K109.00K-2.11M-3.01M
Cash Flow
Free Cash Flow-6.66M-8.32M-6.57M-2.56M-2.89M-3.82M
Operating Cash Flow-6.63M-8.19M-6.16M-2.17M-2.89M-3.82M
Investing Cash Flow-195.00K-2.49M-477.00K-386.00K262.00K1.60M
Financing Cash Flow10.53M11.62M6.30M4.64M2.04M2.04M

Firefly Neuroscience Technical Analysis

Technical Analysis SentimentNegative
Last Price0.91

Price Trends

50DMA1.13Negative
100DMA1.13Negative
200DMA1.37Negative

Market Momentum

MACD-0.05Negative
RSI41.85Neutral
STOCH29.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.13, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 29.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIFF.

Firefly Neuroscience Risk Analysis

Firefly Neuroscience disclosed 73 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may not continue to meet the continued listing requirements of Nasdaq, which could result in a delisting of our common stock.Q3, 2024
2.Our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.Q3, 2024
3.We currently take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors.Q3, 2024

Firefly Neuroscience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

AIFF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
NMTCNMTC49Neutral$6.78M-0.82-126.45%―-1.67%7.34%
IRTCIRTC46Neutral$3.05B-77.37-22.80%―21.56%27.87%
AIFFAIFF44Neutral$13.94M-1.79-71.97%―162.84%80.71%
CGTXCGTX43Neutral$60.75M-3.82-50.57%――62.99%

* Technology Sector Average

Performance Comparison

-50%0%50%AIFFIRTCNMTCCGTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AIFF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AIFFFirefly Neuroscience, Inc.0.91-0.67-42.28%
IRTCIrhythm Technologies89.67-77.52-46.37%
NMTCNeuroone Medical Technologies Corporation0.71-3.07-81.32%
CGTXCognition Therapeutics, Inc.0.63-0.76-54.75%

Firefly Neuroscience Corporate Events

Executive/Board Changes

Firefly Neuroscience Reshapes Finance and Accounting Leadership

Neutral
Sep 14, 2026

On September 8, 2026, Firefly Neuroscience’s board of directors terminated Chief Financial Officer Paul Krzywicki, effective September 24, 2026, with the company stating the decision did not stem from disagreements over operations, policies or practi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026